Search
Showing results for "early lung health"
Mannitol challenge tests are used clinically to diagnose asthma and, in particular, exercise-induced broncoconstriction (EIB) in adults and children above 6...
COMBAT CF is one of two long-standing international trials which have resulted in new early intervention options helping to reduce progressive lung damage in kids living with CF.
One in eight children have asthma, a chronic disease of the airways in the lungs. It results in shortness of breath, chest tightness, wheezing and coughing.
This review will discuss the necessary steps required for a Bayesian adaptive platform trial to optimize treatment of pulmonary exacerbations of cystic fibrosis
Dr Katherine Alexander Landwehr Larcombe BSc(Hons) BScEnv (Hons) PhD Senior Research Officer Honorary Research Fellow Katherine.landwehr@
Most asthmatics would prefer workplaces, healthcare facilities, and environments that are fragrance-free, which could help reduce adverse effects
Remote Aboriginal communities in Australia are located on traditional lands holding deep cultural significance and meaning for residents. However, systemic inequity rooted in colonisation has driven persistent housing and health disparities, with inadequate environmental health conditions within homes and communities a prominent example.
Cystic fibrosis (CF) is a rare, inherited, life-limiting condition predominantly affecting the lungs, for which there is no cure. The disease is characterized by recurrent pulmonary exacerbations (PEx), which are thought to drive progressive lung damage. Management of these episodes is complex and generally involves multiple interventions targeting different aspects of disease. The emergence of innovative trials and use of Bayesian statistical methods has created renewed opportunities for studying heterogeneous populations in rare diseases.
An intensive health promotion campaign which aims to raise awareness of the dangers of a chronic wet cough in Aboriginal children launched this month in Perth.
This study aimed to investigate acamprosate and naltrexone dispensing patterns in Australia.